Trial Profile
Non-inferiority Phase II Trial Comparing BL123 (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2016
Price :
$35
*
At a glance
- Drugs Dapaconazole (Primary) ; Ketoconazole
- Indications Pityriasis versicolor; Tinea pedis
- Focus Therapeutic Use
- 08 Jun 2016 New trial record